Results you can trust
The first and only FDA-approved PD-L1 test for use in both non-squamous NSCLC and melanoma for OPDIVO® (nivolumab).
PD-L1 Pathology Training
The PD-L1 IHC 22C3 pharmDx Pathology Training Program helps to educate on evaluating PD-L1 expression in patients with NSCLC for Keytruda® (pembrolizumab).
Leading the way
in PD-L1 testing
Introducing the first and only FDA-approved test to assess patients with NSCLC for KEYTRUDA® (pembrolizumab).
View CAP Today and Dako webinar
Standards for IHC Controls:
with Clive Taylor, M.D., DPhil, FrcPath
Next Generation Cancer Profiling
Parallel DNA sequencing of cancer-associated targets.
Atlases of Stains
Read our Atlas of Stains (FLEX Ready-to-Use) and our Atlas of Special Stains.
Sixth Edition of IHC Guidebook
Read the sixth edition of the popular educational guidebook, used by pathology laboratories worldwide.
Free IHC Webinar
Standards for IHC Controls: Expert Recommendations by Clive R. Taylor.